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Abstract
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is singlestranded, positive-sense RNA virus in the family Arteriviridae, order Nidovirales.
PRRSV is the most economically significant viral infection of swine herds in the
United States. The single-stranded RNA genome is 15 kb in length and encodes 9
open reading frames (ORF1a, ORF1b, ORF2a, ORF2b and ORFs 3 through 7).
ORFs 1a and 1b encode for 13 non-structural proteins (nsp) that are suggested to
be involved in transcription and viral genome replication. The exact role of nonstructural proteins in PRRSV cycle is still unknown. Moreover, there is a limited
availability of reagents such as antibodies against these non-structural proteins that
further limits their study. To overcome that limitation, the gene coding for nonstructural protein 3 (nsp-3) was synthesized using the polymerase chain reaction
(PCR) and cloned in-frame into a plasmid vector to create a construct named
pRSETA-nsp3. After transforming Escherichia coli with pRSETA-nsp3, individual
colonies that grew in the presence of ampicillin were selected. These colonies were
cultured in terrific broth-ampicillin media. Then, plasmid DNA was extracted to
evaluate for the presence and fidelity of the nsp-3 gene by means of agarose gel
electrophoresis separation and sequencing. DNA plasmids harboring a correct copy
of the gene were used to express nsp-3 protein in BL21 competent Escherichia coli
cells. After growth of BL21 transformants in “Magic media”®, expression of nsp-3
was assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) separation
followed by Coomassie blue staining and western blot detection using an anti Histag monoclonal antibody.

PRRSV nsp-3 was then purified by metal affinity
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chromatography.

Purified nsp-3 protein will be used to produce an anti nsp-3

polyclonal antibody serum in rabbits for further study of the functions of this protein.
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Chapter 1
Porcine Reproductive and Respiratory Syndrome
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1.1 Introduction
Porcine reproductive and respiratory syndrome virus is an arterivirus and the
etiological agent of porcine reproductive and respiratory syndrome (PRRS). This
syndrome is a disease of great interest especially with respect to the United States
and European pork industries. PRRS syndrome has been described as “the most
economically important infectious disease of swine production” (Music and Gagnon,
2010). It was first discovered in the United States in 1987 and then in the
Netherlands in the following years. The main symptoms include severe reproductive
failure in gilts and sows, and respiratory problems in pigs of any age group. This
very serious disease has caused many economic and production obstacles, costing
swine industries almost $600 million/year in the United States (Neumann et al.
2005).
The virus can establish a chronic infection in swine macrophages in vitro and
as studies show, it causes cell induced apoptosis or necrosis as well as chronic
PRRSV infection (Cafruny et al., 2006). This virus began to emerge in North
America in 1987 and was first identified in 1992 by Collins et al. In Europe, the virus
was detected in 1990 and was first identified in the Netherlands by Wensvoort et al.
in 1991 (Wensvoort et al, 1991).
Because PPRSV belongs to the family of Arteriviridae, the viral particles are
characterized by a spherical shape with a diameter of 40-60 nm and are enveloped.
Consistent with other arteriviruses such as Equine Arteritis Virus (EAV), PRRSV has
the ability to establish chronic infection in swine host cells, with macrophages being
the main target cells. Thus, PRRSV causes a debilitating illness in swine. This virus
can manufacture its own structural and nonstructural proteins to administer its
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functions. The nonstructural proteins allow the virus to replicate within permissive
cells of the host. When this occurs repeatedly, cell after cell is destroyed in the host
organism and its immune system is heavily burdened. Therefore over time, the host
organism is at increasingly higher risk. The symptoms of PRRS range from none to
acute hemorrhagic fever and abortion (Collins et al., 1992).

1.2 The economic significance of PRRS
PRRSV has played a significant role in the US swine industry in the modern
day. A case study done by Neumann et al. 2005 from the Office of Swine Health
Information and Research of the National Pork Board, shows the analytical results
of the impact on the United States economy (Table 1). PRRSV affected and
unaffected farms were compared in health and productivity, considering parameters
such as farrowing rate (the rate of parturition in the sow), pigs weaned per litter, and
pigs weaned/sowed per year. In that study, the number of affected litters and the
duration of the PRRSV outbreak were recorded and analyzed against data obtained
from farms not affected by PRRSV to calculate the total cost of the disease per
farm. Utilizing national estimates of PRRSV prevalence among swine herds, the
total annual economic impact of the disease was estimated for the US pork
industry.
It has been reported that there was high variability among affected farms in
terms of duration of PRRSV outbreaks. While a certain proportion of affected farms
had a markedly clear period of occurrence of the disease, usually ending with
implementation of immunological control measures, other farms suffered from
chronic exposure to PRRSV. Farrowing rates in PRRSV-affected farms tend to
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decrease by a mean of 13.76%, with a negative impact on productivity of 16.43%.
The effect of the viral infection on the number of pigs weaned/sowed showed a
drastic decrease of 2.3 to 11.2 pigs per year. Analysis of mortality rates of nurseryage pigs in two PRRSV infected farms showed a mean increase of 10.65%,
although with relatively large variability. For pigs in the grower-finisher phase of
production, the amount of feed necessary to sustain these animals increased,
translating to a mean loss of feed efficiency of 7.57%. Furthermore, there was a
substantial increase in the mortality rate up to 6.05% in this category of animals.

Table 1: Projected annual cost of PRRS to US swine producers as described by
Neumann, 2005).
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Through an economic lens, these data prove quite staggering, with a total
reduction of revenue of $45 per litter. A cost increase of $3.58 per nursery-phase
pig and $3.23 per grower-finisher phase pigs was calculated. To US swine
producers as a whole, the total increased cost of PRRSV-affected swine, is $560.32
million/year. This is based on a sum of calculated increased costs for PRRSV
affected pigs of the nursery, breeding-farrowing, and grower-finisher phases. The
total cost attributed to classical swine fever in 1961 was $364.09 million after
inflation adjustment. The relatively higher cost corresponding to PRRSV today
demonstrates that PRRSV is a successful, and thus important, pathogen.

1.3 Clinical manifestation of PRRS
PRRS exhibits a number of distinct clinical manifestations with respect to two
discriminatory pathological classes: reproductive failure and respiratory ailments.
This syndrome is characterized by “late-term abortions, an increased number of
stillbirths, mummified and weak-born pigs,” and “non-specific lymphomononuclear
interstitial pneumonitis,” which is a type of inflammation of the lungs (Music and
Gagnon, 2010). Other features of the disease include “anorexia, fever, lethargy,
pneumonia, agalactia, red/blue discoloration of the ears and vulva, subcutaneous
and hind limb edema, delayed return to estrus after weaning, and in rare cases,
death” (Done and Paton, 1995; Rossow, 1998; Terpstra , 1991).
The degree of respiratory ailment varies with age, but is most severe in young
swine. Neonatal pigs are affected up to 100% with mortality. Live born pigs infected
with PRRSV in utero may exhibit clinical signs of edema in the periocular region and
eyelids. Shaking, diarrhea, and neurological signs can also be observed. Weaning
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pigs show failure to thrive, lethargy, and fever. The disease also renders young pigs
vulnerable to concurrent infections, as its compromised immune system may
succumb to secondary bacterial or viral pathogens, such as Streptococcus suis type
2, swine influenza virus, and porcine respiratory coronavirus. In fact, pneumonia is
not an uncommon clinical sign in weaning pigs as well.
In the post-weaning phase, there is a body temperature increase ranging from
1 to 3 degrees C above normal which can last up to four days after infection (Knox,
2005).

In a more severe infection PRRSV lesions are consistent with enlarged

lymph nodes and interstitial pneumonia including lungs that fail to recoil. The most
documented occurrence of PRRSV-induced lesions are a result of interstitial
pneumonia, a form of lung disease characterized by scar tissue present on both
lungs, and in the case of neonatal pigs, leaked alveolar exudate with large quantities
of necrotic debris and immune cells. Other less common lesions can occur in
lymphoid tissue and are marked by hypertrophy, necrosis, and cystic spaces
between lymph nodes. Finishing pigs, which are pigs in a higher weight class
fattened for slaughter, and boars are less likely to express any clinical signs and a
blood test may be the only means to determine infection (Done and Paton, 1995;
Rossow, 1998).
The reproductive phase of the disease generally causes abortions 2 to 3
weeks post-infection, if the pig is in the second half of the gestation period. Another
clinical occurrence is premature delivery, usually of a mixture of live and dead
fetuses. There is an increase in the number of stillborn pigs as well as mummified
fetuses. Fetal mummification is the shriveling of a retained unborn offspring in the
uterus. Reproductively, the sow is also affected with decreased capacity to produce
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milk. Males may demonstrate low quantity or abnormal sperm cells. If a female
mates with an infected male, she may become infected and fail to conceive (Knox,
2005).
The severity of the disease depends on a number of factors. Virus virulence
varies with different PRRSV isolates. For example, in a study by Halbur et al, 5-week
old pigs of the same breed and cesarean-derived, were infected with 9 different
PRRSV isolates of the North American strain. The researchers discovered that there
were major differences in pathogenicity among the isolates (Halbur et al, 1996). In
addition to genetic differences that give rise to varying pathogenicities of different
PRRSV isolates, another factor of severity seems to be the swine breed. To
illustrate, a study done by Vincent et al in 2006 shows significant differences in
clinical signs of two genetically distinct commercial lines of pigs that were infected
with a known highly virulent strain of PRRSV (VR-2385) (Vincent et al., 2006). Other
factors include age of the pig and the occurrence of other secondary infections that
may have compromised the immune system.

1.4 Transmission of PRRS
Transmission seems to increase with proximity of the animals as the main
means of virus spread is via aerosols. This suggests that even pigs that are not in
direct contact but are still housed together in close conditions are still susceptible
infection. In fact, “aerosol transmission from farm to farm across miles is suspected,
but as of yet, has not been proven” (Knox, 2005). Once it enters the respiratory
tract, PPRSV will replicate and disseminate to multiple organs where it mainly
targets macrophages, especially in the lungs and bronchiolar epithelial cells, as well
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as arteriolar endothelial cells and monocytes. Virus is also shed in urine, feces, and
semen of infected boars as well as a variety of other secretions such as saliva, nasal
fluid, serum and mammary gland secretions. PRRSV has the ability to cross the
placenta and so, the fetuses that have contracted the virus in utero and survive are
major concerns for farmers as they can be carriers after birth (Knox, 2005).
Indirect transmission is also possible and mainly results from common
farming practices like non-sterile use of needles and practices that generate
aerosols. Insects might be another method of transfer (Otake et al., 2003). The
virus has also been isolated on clothing, saliva, and fingernail washings of personnel
in direct contact with infected animals, and as a particular study shows, they were
able to transmit the virus to non-infected animals (Knox, 2005). However, there is
no evidence supporting transmission of PRRSV via rodents or birds (Knox, 2005).
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Chapter 2
Control of PRRSV infections
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2.1 PRRSV vaccines
Currently, there are live and killed vaccines against PRRSV. However, these
vaccines are not highly effective, and are probably affected by different factors,
including viral loads of the affected herds, virulence of circulating PRRSV,
concurrent illnesses, or genetic predispositions of the pigs (Knox, 2005). Current
vaccinations mainly rely on the use of live attenuated vaccines (LAV). The first LAV
against PRRSV was developed in 1994 via attenuation of the virus by successive
passages in a permissive monkey kidney derived cell line (MARC-145) (Kim, 1993).
These LAVs were able to confer protection against homologous virus but failed to
protect swine against heterologous PRRSV strains (Plana-Duran et al, 1997).
Although LAVs do not confer an efficacious protection against PRRSV and do not
confer a long lasting immunity, they reduce the occurrence of fever, abortions, and
transmission of the virus (Kimman, 2009). Killed PRRSV vaccines are even less
efficacious than LAVs particularly in their capability to reduce virus transmission. The
efficacy of killed vaccines might be improved by the use of more effective adjuvants
(Linghua et al, 2007).
Besides their efficacy, a major concern with LAVs is their safety. Live viruses,
attenuated or virulent, have the ability to cross the placenta and cause in utero
infections of fetuses, so their use in pregnant sows is counter indicated.
Furthermore, LAVs persist in vaccinated animals and may revert to a pathogenic
phenotype as observed after large-scale vaccination of Danish swine herds (Botner,
1997; Nielsen, 2001). Also, it has been suggested that PRRSV can exist as a quasispecies leading to decreased efficacy of vaccines due to the appearances of novel
variants in infected animals. In addition to this, multiple variants of PRRSV can exist
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on farms in different individuals at the same time (Music and Gagnon, 2010). More
conclusive studies done on the PRRSV proteins, nonstructural in particular, may
provide better insight into the modification of a live-attenuated virus that would
benefit swine health.
Experimentally, other types of vaccines against PRRSV have been designed
such as DNA vaccines. DNA vaccines using ORF 5 induced high levels of
neutralizing antibodies (Barfoed et al, 2004), suggesting promising results. More
recently, small interference RNAs (siRNAs) have been tested as antiviral tools.
siRNA targeting ORF 1a-b and ORF 7 inhibited PRRSV growth in vitro (Patel et al,
2008). Although this anti-viral method has proven effective, it is still only in an in vitro
stage. Clearly, live attenuated PRRS vaccines of improved safety, efficacy, and
utility are needed. Better understanding of viral genetic determinants critical for viral
virulence and host range, including those which allow current LAVs to efficiently
infect and spread in susceptible cells and tissues and persist in the pig, will permit
rational design of improved PRRS LAVs.

2.2 Herd management
Other key methods for controlling PRRSV spread within and among farms are
based on herd management. These non-vaccination based methods include several
approaches such as prevention of contact between newly introduced pigs and an
established herd until outbreaks of infection subside, disinfection of newly introduced
animals, isolation of infected animals, ensuring use of non-infected semen when
practicing artificial insemination, and establish biosecurity methods to avoid indirect
transmission of the virus (Knox, 2005).
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Chapter 3
Porcine Reproductive and Respiratory Syndrome Virus

18
3.1 The Virion
PRRSV is an enveloped virus of spherical shape. Virions harbor a singlestranded positive sense RNA viral genome of 15 kb in length, capped at the 5’ end
and polyadenylated at the 3’ end. As a member of the family Arteriviridae and the
genus Arterivirus, it is very similar to EAV and Simian Hemorrhagic Fever Virus
(SHFV) (Figure 1).

GP5

M GP2a

E
GP3

GP4

Lipid bilayer

Nucleocapsid

GenomicRNA
Figure 1: Schematic representation of PRRSV virion. GP: glycoproteins, E: envelope
proteins, and M: matrix protein.

The viral envelope (lipid bilayer) can be maintained only within a certain range
of environmental conditions. Outside from its natural host (i.e. swine), PRRSV
remains stable in a -70 to -20˚C temperature range. PRRSV can survive in a 6.5 to
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7.5 pH range.

Some detergents have proved effective at disrupting the viral

envelope (Music and Gagnon, 2010).
3.2 Genetic diversity among PRRSV types
There are at least two distinct genotypes recognized for this heterogeneous
virus, one endemic to Europe (Type 1) and one endemic to North America (Type 2).
Although the two genotypes share many similarities, such as genome organization,
they are distinguished genetically (Music and Gagnon, 2010). PRRSV isolates, from
both the North American and European types, vary in antigenic capacity. There are
similarities at the level of amino acid sequence ranging from 96-100% within Type 2
North American PRRSV, but when compared to the European isolates, identities
range between 57-81% (Meng et al, 1995).
3.3 PRRSV genome
The PRRSV genome encodes for nine open reading frames (ORFs) (Figure
2). Structural proteins are encoded for by open reading frames (ORFs) 2 to 7, while
the non-structural proteins are encoded by ORF1a and ORF1b. All ORFs are
expressed through the production of a nested set of subgenomic 3’ coterminal
mRNAs.

RFS
5’ cap

ORF 1a

ORF1b

Non-structural proteins

GP2

E

GP4
GP3

M
GP5

N

Poly A 3’

Structural proteins

Figure 2: schematic representation of PRRSV genome indicating the location of
different open reading frames encoding for non-structural and structural proteins.
ORF: open reading frame, GP: glycoprotein; E: envelope protein; M: matrix protein; N:
nucleocapsid protein; RFS: ribosomal frameshift (Adapted from Fang and Snijder,
2010).
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ORF1a and ORF1b encode for the proteins (n=12) that compose the PRRSV
replication complex (Figure 3). These ORFs constitute two-thirds of the entire viral
genome. ORF1a and ORF1b encode polyproteins 1a and 1ab that are posttranslationally processed by viral and cellular proteases. While all the nonstructural
and structural proteins of PRRSV are critical for viral replication, nonstructural
proteins 9 to 12 are directly involved in viral transcription and replication.

Pα Pβ CP

SP: nsp-4

Pα Pβ CP
nsp: 1α 1β

SP: nsp-4
2

3

4

5 6 7 8

1a pp
RdRp
9

Hel
10

Ne

1ab pp

11 12

Figure 3: schematic representation of polyproteins (pp) encoded by ORFs 1a and
1a/1b of PRRSV. 1ab pp is produced due to a -1 ribosomal frameshift. Arrows indicate
sites cleaved by nsp-1α and nsp-1β cysteine proteases (CP) Pα and Pβ. Circles
indicate sites cleaved by the viral protease nsp-4 serine protease (SP). nsp: nonstructural proteins . nsp-9 is the RNA dependent RNA polymerase (RdRp). nsp-10
helicase (Hel), and nsp-11 endoribonuclease (Ne). (Adapted from Fang and Snijder,
2010).

ORF2a, 3, and 4 encode for minor structural N-glycosylated proteins GP2a,
GP3, and GP4. ORF 5 encodes for GP5, the major PRRSV glycoprotein. ORF 6
encodes for the membrane protein M, and ORF 7 encodes for the nucleocapsid
protein N.
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3.4 PRRSV structural proteins
The main target cells of PRRSV are mature, well-differentiated cells of the
monocyte-macrophage lineage. In particular, PRRSV infects porcine alveolar
macrophages (PAMs) and interstitial macrophages of other tissues including heart,
thymus, spleen, Peyer’s patches, hepatic sinusoids, renal medullary interstitium, and
adrenal gland (Music and Gagnon, 2010). PRRSV RNA and nucleocapsid proteins
have also been found in other tissues such as testicular germ cells, thymus cells,
endothelial heart cells, bronchiolar epithelial cells, interstitial, alveolar, and
intravascular macrophages, and even dendritic cells of the spleen and Peyer’s
patches.
Entry of PRRSV into target cells is via receptor-mediated endocytosis.
PRRSV receptors on PAMs were identified to be heparan sulphate and
sialoadhesion molecules that allow virus binding and internalization. CD163 is a
molecule expressed only on monocyte-derived host cells that mediates PPRSV
entry (Van Gorp, 2008). High expression of CD163 has been shown to correlate with
increased susceptibility to PRRSV infection. Furthermore, non-permissive cells
transiently expressing both CD163 and sialoadhesion molecules cause a significant
increase in production and propagation of PRRSV (10 to 100 times greater) than
cells transiently expressing only CD163 (Music and Gagnon, 2010).
PRRSV N (nucleocapsid) protein is a multifunctional protein that is important
in virus pathogenesis. N protein is highly immunogenic and can be phosphorylated
in PRRSV-infected cells and synthesized even in the absence of other viral
constituents. Mutational analysis of N suggests that the C-terminus of the protein is
critical to the synthesis of conformational epitopes and the binding of N-specific
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monoclonal antibodies (Music and Gagnon, 2010). The membrane envelope protein
M, together with major glycoprotein envelope protein GP5, is involved in the process
of PRRSV assembly, budding, and virus infectivity (Music and Gagnon, 2010).
These two proteins form heterodimers in infected cells (Mardassi et al., 1996). Refer
to Figure 1.
GP5 is the most abundant of the glycoproteins present in the virion envelope
(Figure 1) and for that reason is called the major envelope glycoprotein, whereas the
GP2, GP3 and GP4 are called minor envelope glycoproteins as they are present in
lesser amounts than GP5 (Das, 2011). The GP2, GP3 and GP4 interact among
themselves and GP5 interacts with both GP4 and M protein (Das et al., 2010;
Mardassi et al., 1996). These interactions are required for assembly of the infectious
virus (Wissink et al., 2005). GP2 and GP4 proteins have been shown to specifically
interact with the CD163 molecule (Das et al., 2010), a receptor for PRRSV entry
(Calvert et al., 2007; Van Gorp et al., 2008).

3.5 PRRSV nonstructural proteins
Understanding the PRRSV life cycle in detail, including the role of
nonstructural proteins, is critical to learning more about its pathology in the host.
Once PPRSV enters the target cells, its replication cycle begins with the release of
the genome into the host cell cytoplasm. The replicase genes located in ORF 1a and
ORF 1b, are expressed as polyproteins pp1a or pp1ab that are translated after
ribosomal frameshifting (-1) (Figure 3). Although not well-understood, pp1a is most
likely cleaved at 8 different sites to form 9 nonstructural proteins, NSP1α, NSP1β,
and NSP2 to 8. These proteins are responsible for a number of intracellular
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interactions including proteolytic activities mediated mainly by NSP4 that result in
further processing of the polyproteins. NSP 9 to 12, are proteins derived from the
cleavage of pp1ab. These proteins seem to have a greater involvement in PRRSV
transcription and replication. NSP 9 is the RNA dependent RNA polymerase (RdRp),
NSP 10 has helicase activity (Hel), and NSP 11 possesses endoribonuclease (Ne)
activity.
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Chapter 4
Rationale and Significance, Objective, and Approach
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4.1 Rationale and Significance
It is essential to identify PRRSV mechanisms involved in induction of disease,
generalization of infection, tissue tropism, host range, and modulation/suppression
of host immune response in order to rationally engineer PRRS biological control
tools. Assessing the roles of PRRSV proteins in the virus life cycle is critical for
understanding virus pathogenesis and virus virulence. Interactions between viral and
host proteins during virus replication within target cells may result in interference
with cellular signaling pathways, ultimately leading to the clinical outcomes observed
during PRRSV infection in swine. To obtain this knowledge on PRRSV virulence and
better elucidate the interactions of PRRSV proteins with host cellular proteins, there
is a need for reagents that would allow detection of those interactions. Thus,
production of reagents such as antibodies to detect specific viral proteins is of
paramount importance for these studies.
4.2 Objective
The objective of this study was to express and purify PPRSV nsp-3, encoded
by ORF1a and part of the viral replication complex. Purified nsp-3 will then be used
for producing reagents such as antibodies. Today, these reagents have a limited
1availability and hamper key studies.
4.3 Approach
Non-structural protein 3, encoded by ORF 1a, is 231 amino acids long (Figure
4) with a predicted molecular weight of 24 kDa (kilo-daltons). Nsp-3 is cleaved by
nsp-4 (Figure 3).
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GGPHLIAALHVACSMALHMLAGVYVTAVGSCGTGTNDPWCTNPFA
VPGYGPGSLCTSRLCISQHGLTLPLTALVAGFGLQEIALVVLIFVSIGG
MAHRLSCKADMLCVLLAIASYVWVPLTWLLCVFPCWLRWFSLHPLT
ILWLVFFLMSVNMPSGILTVVLLVALWLLGRYTNVVGLVTPYDIHHYT
NGPRGVAALATAPDGTYLAAVRRAALTGRTVLFTPSQLGSLLE
Figure 4: Amino acid sequence of NSP 3 from PRRSV isolate NVSL 97-7985
used in this work.

The function of NSP 3 is currently unknown, and the goal of this research is to
express and purify the protein in order to create reagents that will help to identify the
role of NSP 3 in the virus life cycle. In the present work, NSP 3 was expressed fused
to a poly-Histidine tag (6xHis) located at the N-terminus. The poly-His tag creates
an ionized region in the fusion protein that allows binding of the expressed protein to
metals (e.g. nickel or cobalt) to allow purification by metal chromatography. NSP 3
was synthesized by PCR using specific forward and reverse primers and a fulllength cDNA copy of PRRSV isolate NVSL 97-7985 as a target (pFL12, kindly
provided by Dr Fernando Osorio, University of Nebraska-Lincoln). The amplified
NSP 3 gene was inserted in-frame into the pRSET A plasmid (Invitrogen, Carlsbad,
CA) using the T4 DNA ligase (New England Biolabs, Ipswich, MA) where the
expression of the cloned gene is under the control of the T7 promoter. The resulting
plasmid pRSETAnsp-3 was used to transform BL21(DE3)pLysS cells (Invitrogen).
Transformants were then grown in Magic® media (Invitrogen) for maximum
expression of NSP 3. NSP 3 was then purified by affinity chromatography using
nickel columns (Thermo Scientific, Waltham, MA) and was detected by SDS-PAGE
separation followed by Coomassie blue staining and western blotting.
Deleted: ¶
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Chapter 5
Procedures and Results
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5.1 Synthesis of PRRSV NSP3 gene by Polymerase Chain Reaction (PCR)
The purpose of this first step in the process of NSP3 expression is to produce
a high number of copies of the gene. A PCR was designed to synthesize PRRSV
NSP 3 using primers described in table 2. Primers included sequences for BamHI
Deleted:

(ggatcc) and XhoI (ctcgag) restriction sites. A 50 ul reaction was set up as follows:
50 ng of full-length cDNA PRRSV clone pFL12, 5 µL of 10X Advantage PCR buffer
(Clontech, Mountain View, CA), 1 unit of Advantage 2 DNA polymerase (Clontech),
Formatted: Subscript

10 mM dNTPs 10 pmol of each forward and reverse primers, and 34.5µL ddH2O. A
non-template control reaction was run as negative control. Cycling parameters used
were 95°C for two minutes, followed by 35 cycles of 95°C for 30 seconds, 55°C for
45 seconds, and 68°C for 60 second; finished by a final cycle of 68°C for 3 min.
Table 2: sequence of the primers used for PCR amplification of PRRSV NVSL 97-7895
(pFL12 full length cDNA copy) NSP 3 gene. Underlined BamHI and XhoI restriction
sites included in the sequences of NSP3_For and NSP_3Rev primers, respectively.

Primer name

Sequence

NSP 3_For

5’-atggatccggaggcccgcacctcattg-3’

NSP 3_Rev

5’-atctcgagctcaagaagggacccaagctg-3’

5.2 Purification of amplified NSP 3 gene
The 693 bp amplicon of NSP 3 was resolved by agarose gel electrophoresis.
A 1X-TAE buffer (Tris-acetate-EDTA) 1% w/v agarose containing ethidium bromide
was used to separate the amplified DNA. A 1kb DNA ladder (Invitrogen) was used
as molecular size control. Twenty-four µL samples were prepared by mixing 16 µL
of ddH2O, 4µL of 6X loading buffer (Promega), and 4 µL of the PCR reactions.
Samples were loaded into the gels and DNA was separated by running the sample
at 90V for 1 hr (Figure 5).
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M

N NSP3

750 bp
500 bp

Figure 5: PRRSV NSP 3 was amplified by PCR and resolved by agar gel
electrophoresis in a 1% 1X-TAE buffer (Tris-acetate-EDTA) stained with ethidium
bromide. A band of 693 bp was detected. M: 1Kb ladder molecular weight marker
(Invitrogen), N: non-template control.

After separation of the DNA as described above, the NSP 3 was extracted
from the agarose gel using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA)
according with the instructions by the manufacturers. The agarose gel was removed
from the electrophoretic chamber and placed on top of a UV light trans-illuminator to
visualize the DNA band. The band of approximately 700 bp was excised from the gel
using a razor blade and placed in a 1.5 ml microcentrifuge tube. The band was
weighed and 3X volume (e.g. 100 ug = 300 µl of buffer) of Buffer QG was added to
the tube. The tube was placed at 50°C in a heating block and incubated until the
agarose was completely dissolved (~10 min). Then, 200 µL of isopropanol were
added to the tube, mixed, and centrifuged for 1 min at 14,000 rpm in a bench-top
microcentrifuge (Eppendorf, Hauppauge, NY). The entire volume of the sample was
transferred to a QIAquick column and centrifuged for 1 min at 14,000 rpm. The flow-
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through was discarded and 500 µL of Buffer QG were added to the column, followed
by centrifugation for 1 min at 14,000 rpm. The flow-through was discarded and the
column washed once by adding 750 µL of Buffer PE followed by centrifugation for 1
min at 14,000 rpm. The flow-through was discarded and the column centrifuged
again for 1 min at 14,000 rpm to remove residual ethanol. DNA was eluted from the
columns using 50 µl of Buffer EB and centrifuged for 1 min at 14,000 rpm.
Recovered DNA was ready for cloning into pRSET A (Invitrogen) (Figure 6).

Figure 6: Invitrogen’s pRSET diagram. PT7: T7 promoter. RBS: ribosomal binding
site. ATG: codon encoding for methionine. 6xHis: histidine tag. Xpress Eptope:
synthetic epitope tag. EK: enterokinase cleavage site. MCS: multiple cloning sites.
Stop: stop codon. Blue circles denote location of restriction sites for BamHI and XhoI.

5.3 Cloning of the NSP 3 gene into the pRSETA vector
The nsp-3 gene was cloned into pRSETA vector using T4 DNA ligase (New
England Biolabs). Both vector and NSP 3 gene were digested with BamHI and XhoI
restriction endonucleases (New England Biolabs) in a 20 µl reaction. The reaction
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was set as follows: 10 µl of pRSET A (390 ng/ µl) or 10 µl of NSP 3 gene (100 ng/
µl), 2 µl of 10X NEB buffer 2 (New England Biolabs), 0.5 µl of 100X BSA, 1 µl of
BamHI enzyme (20,000U/ml) (New England Biolabs), 1 µl of XhoI enzyme
(20,000U/mL) (New England Biolabs), and 5.5 µl ddH2O. The reaction was then
incubated at 37°C in a water bath for 2 hr. After digestion, linearized pRSET A and
NSP 3 DNAs were resolved in a 1% agarose-TAE-ethidium bromide gel, and a bans
of appropriate sizes were excised and purified from the gel using QIAquick Gel
Extraction Kit (Qiagen) as described above (Figure 7).

M

3 kb

0.75 kb

Figure 7: PRRSV NSP 3 and pRSET A were digested with BamHI and XhoI and
resolved by agarose gel electrophoresis in a 1% 1X-TAE buffer (Tris-acetate-EDTA)
stained with ethidium bromide. M: 1Kb ladder molecular weight marker (Invitrogen),
N: non-template control, NSP 3 gene, and linearized pRSET A (2.9 kb).
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5.4 Ligation reaction
The linearized pRSETA vector and digested nsp-3 gene insert were
combined in a 10 µl ligation reaction. The reaction was set up as follows: 1 µl of
vector, 1 µl of insert, 1 µl of 10X T4 DNA ligase buffer (New England Biolab), and
400 units of T4 DNA ligase (New England Biolab). The reaction was incubated
overnight at 140C. After incubation the ligated DNA was used to transform E. coli
TOP 10 competent cells (Invitrogen).

5.5 Purification of Prseta-nsp3 vector
After transformation, E. coli TOP 10 competent cells were placed on Terrific
Broth (Invitrogen) agar plates containing 50 µg/ml of ampicillin and incubated
overnight at 370C. Ampicillin resistant colonies were picked from the plate and grown
overnight at 370C in Terrific both containing 50 µg/ml of ampicillin. Bacterial cultures
were spun down in bench-top centrifuge at 4000 rpm for 15 minutes to produce a
cell pellet. Supernatant was discarded and plasmid DNA was extracted from the
cells using the QIASpin Miniprep Kit (Qiagen) according with the instructions
provided by the manufacturer. The cell pellet was resuspended in 250µL of Buffer
P1 (kept at 40C before use), this is a cell lysis buffer that contains RNAase. The
suspension was then transferred to a microcentrifuge tube and 250µL of Buffer P2
(high pH buffer) were and mixed thoroughly by inverting the tube 4-6 times. After
mixing, 350µL of Buffer N3 (low pH buffer) were added and rapidly and thoroughly
mixed. The mixture was then centrifuged for 10 min at 14,000rpm to separate
cellular debris from the aqueous phase where plasmid DNA is in solution. The
supernatant was then applied to the QIAPrep spin columns by decanting and the
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tube was centrifuged for 30 sec at maximum speed.

The flow-through was

discarded and the spin column was washed by adding 0.75mL of Buffer PE
containing ethanol and centrifuged again for 30 sec at maximum speed. The flowthrough was discarded and the tube was centrifuged again for 1 min at maximum
speed to remove the residual wash buffer. Plasmid DNA was recovered by placing
the column on top of a clean 1.5 mL microcentrifuge tube, adding 50 µL Buffer EB
(elution buffer) to the center of the column, and spinning 1 min at maximum speed.
Recovered plasmids were digested with BamHI and XhoI as described above
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and resolved in a 1% agarose TAE gel stained with ethidium bromide (Figure 8).
Figure 8. Recovered plasmids were digested with BamHI and XhoI as described above
and resolved in a 1% agarose TAE gel. Arrow indicates the presence of an insert of
appropriate site in clones 2, 4, 6, and 9.
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Deleted:

Clones carrying inserts of the correct size (Figure 8) were sequenced (Genewiz, South

Plainfield, NJ) to further assessing the fidelity of cloned NSP 3 gene. Sequences were
analyzed using Bioedit software.
5.6 Maxiprep of selected pRSETA-nsp3
Once fidelity of the NSP 3 gene in pRSETA was determined, the
concentration of plasmid DNA was increased by using the Hi-speed Plasmid Maxi
Kit (Qiagen). The importance of this step is to increase the amount of nsp-3 (as well
as the plasmid in which it lies) for further research uses. An E.coli stock harboring
pRSETAnsp3 was cultured overnight at 37°C with shaking in 150 ml of Terrific Broth
(Invitrogen) containing 50 µg/ml of ampicillin. After incubation the culture was
centrifuged at 4,000 rpm for 15 min. Supernatant was decanted and the bacterial
pellet was resuspended in 10mL of Buffer P1 incubating for 5 minutes at room
temperature. After thorough mixing by vortexing to resuspend the bacterial pellet, 10
ml of buffer P2 were added and mixed by repeated inversions of the flask. To
neutralize the activity of buffer P2, 10 ml of Buffer P3 were added, mixed gently by
inversion. The mixture was transferred to QIAfilter cartridge and incubated at room
temperature for 10 minutes. In the meantime a HISpeed-tip 500 column was
equilibrated by adding 10mL Buffer QBT and allowed to drain for 10 min. The
content of the QIAfilter cartridge was transferred to the equilibrated a HISpeed-tip
500 column for binding of the DNA to the silica filter. After the flow through was
discarded the column was washed one with 60 ml of Buffer QC. DNA was then
recovered by eluting with 15 ml of Buffer QF. Plasmid DNA was then precipitated by
adding 10.5 ml (0.7 volumes) of isopropanol and incubating at room temperature for
5 min. The eluate/isopropanol mixture was run through a QIAprecipitator and flow-
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through was discarded. The QIAprecipitator was then washed twice with 2 ml of 70%
ethanol and DNA recovered by adding 1ml of Buffer TE. Recovered DNA was then
submitted again for sequencing (Genewiz). This maxiprep was successful and an
increased concentration of plasmid DNA and nsp-3 were produced.
5.7 Expression of PRRSV NSP 3 in E.coli BL21 cells
E. coli BL21 (DE3)pLysS chemically competent cells (Invitrogen) were
transformed with pRSETAnsp3 by heat shock.

Briefly, BL21 cells (50 µl) were

thawed on ice and mixed with 100 ng of pRSETAnsp3. The mixture was incubated
for 30 min on ice. After incubation, the tube containing cells and plasmid DNA was
incubated for 40 sec at 420C in a water bath and place immediately on ice for
additional 2 min. After incubation on ice, 250 µl of SOC media (Invitrogen) were
added to the mixture and incubated at 37oC for 1 hr in an orbital shaker at 250 rpm.
Transformed cells were selected by plating in Terrific Broth agar plates containing
50µg/ml of ampicillin and 35 µg/ml of chloramphenicol, followed by incubation
overnight at 37oC.
Two BL21 cell bacterial colonies were picked from the plate containing the
selective media and transferred to 5 mL of Terrific Broth containing 50 µg/ml of
ampicillin and 35 µg/ml of chloramphenicol and grown with shaking overnight at
37°C. Chloramphenicol selects for maintenance of the pLysS plasmid required for
T7 lysozyme expression and ampicillin selects for the pRSETAnsp3 plasmid. After
incubation, 150 µL of the culture were then added to 150 mL of Invitrogen’s Magic
Media broth. The culture was incubated for 18 hr at 37oC, after which it was
centrifuged at 4,000rpm for 30 min and the supernatant was discarded. The BL21
cell pellet expected to contain expressed NSP 3 kept at -20°C prior to lysis.
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To extract NSP 3, BL21 cells pellets were thawed on ice and 20 mL of
CellLytic B buffer (Sigma, St Louis, MO) containing 100µL of protease inhibitor
(Sigma) was added per 1 g of cells. The pellet was resuspended by pipetting and
vortexing, and further incubated at 37°C for 15 min with shaking. The lysate was
then transferred to 1.5 ml microcentrifuge tubes and centrifuged for 30 min at
13,200rpm. Supernatant was collected and stored at -20°C. To

determine

nsp-3

expression, an SDS-PAGE NuPAGE® Novex 12% Bis-Tris Gel (Invitrogen) was run.
Samples were run under “reducing” conditions by mixing 2.5 µL of NuPAGE® LDS
Sample Buffer (4X), 1µL of NuPAGE® Reducing Agent (10X), and 6.5 µL protein
lysate. Separation of proteins was done in 1X SDS Running Buffer (50 ml 20X
NuPAGE® MES SDS Running Buffer in 950 ml of ddH2O). A molecular size marker
was run next to the cell lysates (Novex® Sharp Pre-stained Protein Standard,
Invitrogen). The gel was run at 200V for 35 min. After separation, the gel was
transferred to a clean tray and stained with Coomasie blue (SimplyBlue Self Stain,
Invitrogen) (Figure 9). The result was a dark stain in the 25-31 kDa region indicating
the presence of nsp-3 in high concentration.

M

CL
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20 kDa

Figure 9. BL21 cell protein lysates (CL) were separated by SDS-PAGE using a
NuPAGE® Novex 12% Bis-Tris Gel (Invitrogen) and stained with SimplyBlue Self Stain
(Invitrogen). M: molecular size marker expressed in kDa.

The fusion protein expressed from pRSETA-nsp3 in BL21 cells (Figure 10) is
expected to have a molecular size of approximately 29 kDa.
Deleted:

MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSGGPHLIAALHV
ACSMALHMLAGVYVTAVGSCGTGTNDPWCTNPFAVPGYGPGSLCTSRLCI
SQHGLTLPLTALVAGFGLQEIALVVLIFVSIGGMAHRLSCKADMLCVLLAIAS
YVWVPLTWLLCVFPCWLRWFSLHPLTILWLVFFLMSVNMPSGILTVVLLVAL
WLLGRYTNVVGLVTPYDIHHYTNGPRGVAALATAPDGTYLAAVRRAALTGR
TVLFTPSQLGSLLE
Figure 10: Amino acid sequence of PRRSV NSP3 fusion protein expressed in this
work. In red is the fused sequence that includes 6x-His, Express® epitope, and
enterokinase cleavage site sequences.
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5.8 Purification of NSP3

This time, purification was carried out of the nsp-3 grown in Magic Media.
Chemically competent One Shot BL21 (DE3) pLysS E. coli (Invitrogen) cells were
transformed with 10 ng of pRSETAnsp3 plasmid encoding PRRSV nsp-3, cultured in
Magic Media (Invitrogen) for 21 hours at 37°C with shaking, and harvested by
centrifugation at 4,000 rpm for 15 minutes. Cell pellets were then treated with
CelLytic buffer (Sigma Aldrich, St. Louis, MO) according to the manufacturer’s largescale extraction protocol. For His-tagged protein purification, cell lysates were
applied to HisPur Cobalt Spin Columns (Thermo Fisher Scientific, Rockford, IL).
Briefly, the 3mL capacity spin columns were equilibrated at room temperature and
protein lysates were thawed on ice for 30 min before purification. The bottom plug at
the bottom of the column and storage buffer was allowed to drain out by gravity.
The spin column was equilibrated by adding two volumes of resin bed in 6 mL of
Equilibration/Wash Buffer with the cap at the bottom of the column in place. The
column was allowed to sit for 4 min before use. After this equilibration step, the
columns were inverted a few times and the Equilibration/Wash Buffer was drained
from the columns for 4 min. To purify nsp-3, the protein lysate was mixed with an
equal volume of Equilibration/Wash Buffer and vortexed. The bottom of the column
was capped and the protein lysate was applied to the spin column. The spin column
was inverted several times to mix and incubated on ice for 80 min with vigorous
shaking. During this incubation, the spin column was shaken vigorously by hand
every 2 to 3 min to ensure that resins do not form a packed pellet. The spin column
was then placed on the top a 15 mL centrifuge tube and drained by removing the
bottom cap and loosening the top cap. The flow through was collected, labeled
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Collection 1 and kept on ice. The resin in the column was washed with 2 volumes of
Equilibration/Wash Buffer and incubated for 4 min. The flow-through was collected in
a new 15 ml centrifuge tube and it was labeled Wash 1. The process was repeated
two more times and Wash 2 and Wash 3 were collected. His-tagged nsp-3 was
eluted from the resin by adding one resin-bed volume of Elution Buffer and
incubating for 4 min.

After incubation the flow-through was collected in 15 ml

centrifuge tube and labeled Elution 1. The same process was repeated two more
times so that Elutions 2 and 3 could be collected. All fractions were stored at -200C.
Collected fractions were then analyzed on a 10% NuPage Novex Bis-Tris gel
(Invitrogen) using a discontinuous SDS-PAGE system as described above. The gel
was stained using Simply Blue (Invitrogen) (Figure 11). Though the band is very
faint, the gel picture still shows the presence of nsp-3, although the protein-yield was
low.
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C1 W1 E1
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20 kDa

Figure 11. Purification of His-tagged PRRSV NSP 3. SDS-PAGE electrophoresis
stained with Simple Blue (invitrogen). M: molecular size markers expressed in kDa.
C1: collection 1. W1: wash 1. E1: elution 1. Arrow indicates NSP 3 His-tagged fusion
with a molecular size of 28 kDa.

5.9 Detection of NSP3 by Western Immunoblot
To specifically detect NSP 3, protein lysates from BL21 cells transformed
with pRSETAnsp3 were run in a SDS-PAGE under the conditions described above.
After the run, proteins were transferred to a PVDF (polyvinylidene difluoride)
membrane (Invitrogen). To perform the transfer, the gel is layered next to the PVDF
membrane and placed in a voltage gradient perpendicular to the gel (X Cell II Blot
Module, Invitrogen). Negatively charged molecules (i.e. proteins) will migrate out
from the gel, move towards the positive electrode, and get transferred to the
membrane. The transfer buffer for reducing conditions was set by combining 50 mL
of NuPAGE® Transfer Buffer (20X), 1 mL NuPAGE® Antioxidant, Methanol* 100
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mL, and 849 ml of ddH2O. Before transferring the PVDF membrane was activated in
methanol for 30 seconds and then transferred to 100 ml of transfer buffer. The
transfer was run for 70 min at 30V, 170mVa using the X Cell II Blot Module
(Invitrogen).
After transfer the PVDF membrane was washed three times for 5 minutes
with ddH2O. The membrane was then blocked for 90 minutes in blocking buffer
(WesternBreeze Chemiluminescent immunodetection kit, Invitrogen) containing 5mL
water, 2mL Blocker/Diluent A, and 3mL Blocker/Diluent B. After blocking, the
membrane was washed with ddH2O twice for 5 min. The membrane was incubated
with the primary antibody, an anti-His tag monoclonal antibody (Invitrogen) diluted
1:2000 in a buffer containing 7mL of ddH2O, 2mL of Blocker/Diluent A, and 1mL
Blocker/Diluent B for 60 min at room temperature. The membrane was then washed
three times with antibody wash buffer containing 10mL of antibody wash, and 150mL
of ddH2O, for 5 min at room temperature. After washing, the membrane was
incubated with the secondary anti-mouse antibody in a buffer containing 10 ml of
secondary antibody solution and 4 µL of goat anti-mouse alkaline phosphatase
conjugated antibody for 35 min. The membrane was washed twice for 5 min with
ddH2O to remove unbound secondary antibody. Using a clean pipette 2.5 ml of
alkaline phosphatase Chemiluminescent substrate were placed on top of the PVDF
membrane and the reaction was allowed to proceed for 5 min. Excess substrate was
removed with a paper filter without allowing the membrane to dry out. The
membrane was then covered with a transparency and exposed to a Kodak X-OMAT
AR film for several minutes. The substrate-enzyme reaction releases light that is
captured by the X-ray film (Figure 12). Using this approach a protein of
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approximately 28 kDa was detected by western immunoblot using an anti His-tag
monoclonal antibody.

NSP3

30 kDa
20 kDa

Figure 12. Western immunoblot showing His-tagged PRRSV NSP 3.
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Summary
NSP 3 from PRRSV isolate NVSL 97-7985 was synthesized by PCR
amplification, cloned into E. coli expression vector pRSET A, and expressed in E.
coli BL21 (DE3) pLysS. PRRSV NSP 3 was purified by affinity chromatography and
its purity verified by SDS-PAGE and Western immunoblot using a monoclonal
antibody against the 6xHis tag. A variety of molecular techniques were used and
successfully adjusted during the course of this work, including DNA amplification,
protein expression, protein separation, and protein purification. Overall the objective
of this work was fulfilled.
PRRSV NSP 3 will be used for production of antibodies. These antibodies
against PRRSV NSP 3 are critical for studies such as protein-protein interactions
between viral and host proteins.

44
References
Barfoed, A.M., Blixenkrone-Moller, M., Jensen, M.H., Botner, A. and Kamstrup, S.
(2004) DNA vaccination of pigs with open reading frame 1-7 of PRRS virus.
Vaccine 22(27-28), 3628-41.
Botner, A., Strandbygaard, B., Sorensen, K.J., Have, P., Madsen, K.G., Madsen,
E.S. and Alexandersen, S. (1997) Appearance of acute PRRS-like symptoms
in sow herds after vaccination with a modified live PRRS vaccine. Vet Rec
141(19), 497-9.
Cafruny, W.A., Duman, R.G., Wong, G.H., Said, S., Ward-Demo, P., Rowland, R.R.
and Nelson, E.A. (2006) Porcine reproductive and respiratory syndrome virus
(PRRSV) infection spreads by cell-to-cell transfer in cultured MARC-145 cells,
is dependent on an intact cytoskeleton, and is suppressed by drug-targeting
of cell permissiveness to virus infection. Virol J 3, 90.
Calvert, J.G., Slade, D.E., Shields, S.L., Jolie, R., Mannan, R.M., Ankenbauer, R.G.
and Welch, S.K. (2007) CD163 expression confers susceptibility to porcine
reproductive and respiratory syndrome viruses. J Virol 81(14), 7371-9.
Collins, J.E., Benfield, D.A., Christianson, W.T., Harris, L., Hennings, J.C., Shaw,
D.P., Goyal, S.M., McCullough, S., Morrison, R.B., Joo, H.S. and et al. (1992)
Isolation of swine infertility and respiratory syndrome virus (isolate ATCC VR2332) in North America and experimental reproduction of the disease in
gnotobiotic pigs. J Vet Diagn Invest 4(2), 117-26.
Das, P.B., Dinh, P.X., Ansari, I.H., de Lima, M., Osorio, F.A. and Pattnaik, A.K.
(2010) The minor envelope glycoproteins GP2a and GP4 of porcine

45
reproductive and respiratory syndrome virus interact with the receptor CD163.
J Virol 84(4), 1731-40.
Das, P.B., Vu, H.L., Dinh, P.X., Cooney, J.L., Kwon, B., Osorio, F.A. and Pattnaik,
A.K. (2011) Glycosylation of minor envelope glycoproteins of porcine
reproductive and respiratory syndrome virus in infectious virus recovery,
receptor interaction, and immune response. Virology 410(2), 385-94.
Done, S.H. and Paton, D.J. (1995) Porcine reproductive and respiratory syndrome:
clinical disease, pathology and immunosuppression. Vet Rec 136(2), 32-5.
Fang, Y. and Snijder, E.J. (2010) The PRRSV replicase: exploring the
multifunctionality of an intriguing set of nonstructural proteins. Virus Res
154(1-2), 61-76.
Halbur, P.G., Paul, P.S., Meng, X.J., Lum, M.A., Andrews, J.J. and Rathje, J.A.
(1996) Comparative pathogenicity of nine US porcine reproductive and
respiratory syndrome virus (PRRSV) isolates in a five-week-old cesareanderived, colostrum-deprived pig model. J Vet Diagn Invest 8(1), 11-20.
Kim, H.S., Kwang, J., Yoon, I.J., Joo, H.S. and Frey, M.L. (1993) Enhanced
replication of porcine reproductive and respiratory syndrome (PRRS) virus in
a homogeneous subpopulation of MA-104 cell line. Arch Virol 133(3-4), 47783.
Kimman, T.G., Cornelissen, L.A., Moormann, R.J., Rebel, J.M. and StockhofeZurwieden, N. (2009) Challenges for porcine reproductive and respiratory
syndrome virus (PRRSV) vaccinology. Vaccine 27(28), 3704-18.
Knox, Robert V. "PRRS Is Still A Mystery Disease” (Swine Reproduction) University
of

Illinois

Extension.

Illinois

Livestock

Trail

(2011).

46
http://www.livestocktrail.uiuc.edu/swinerepronet/paperDisplay.cfm?ContentID
=7595>.
Linghua, Z., Xingshan, T. and Fengzhen, Z. (2007) Vaccination with porcine
reproductive

and

respiratory

syndrome

killed

virus

vaccine

and

immunostimulatory oligodeoxynucleotides induces specific immunity in
piglets. Vaccine 25(10), 1735-42.
Mardassi, H., Massie, B. and Dea, S. (1996) Intracellular synthesis, processing, and
transport of proteins encoded by ORFs 5 to 7 of porcine reproductive and
respiratory syndrome virus. Virology 221(1), 98-112.
Meng, X.J., Paul, P.S., Halbur, P.G. and Lum, M.A. (1995) Phylogenetic analyses of
the putative M (ORF 6) and N (ORF 7) genes of porcine reproductive and
respiratory syndrome virus (PRRSV): implication for the existence of two
genotypes of PRRSV in the U.S.A. and Europe. Arch Virol 140(4), 745-55.
Music, N. and Gagnon, C.A. (2010) The role of porcine reproductive and respiratory
syndrome (PRRS) virus structural and non-structural proteins in virus
pathogenesis. Anim Health Res Rev 11(2), 135-63.
Neumann, E.J., Kliebenstein, J.B., Johnson, C.D., Mabry, J.W., Bush, E.J.,
Seitzinger, A.H., Green, A.L. and Zimmerman, J.J. (2005) Assessment of the
economic impact of porcine reproductive and respiratory syndrome on swine
production in the United States. J Am Vet Med Assoc 227(3), 385-92.
Nielsen, H.S., Oleksiewicz, M.B., Forsberg, R., Stadejek, T., Botner, A. and
Storgaard, T. (2001) Reversion of a live porcine reproductive and respiratory
syndrome virus vaccine investigated by parallel mutations. J Gen Virol 82(Pt
6), 1263-72.

47
Otake, S., Dee, S.A., Rossow, K.D., Moon, R.D., Trincado, C. and Pijoan, C. (2003)
Transmission of porcine reproductive and respiratory syndrome virus by
houseflies (Musca domestica). Vet Rec 152(3), 73-6.
Patel, D., Opriessnig, T., Stein, D.A., Halbur, P.G., Meng, X.J., Iversen, P.L. and
Zhang, Y.J. (2008) Peptide-conjugated morpholino oligomers inhibit porcine
reproductive and respiratory syndrome virus replication. Antiviral Res 77(2),
95-107.
Plana-Duran, J., Bastons, M., Urniza, A., Vayreda, M., Vila, X. and Mane, H. (1997)
Efficacy of an inactivated vaccine for prevention of reproductive failure
induced by porcine reproductive and respiratory syndrome virus. Vet
Microbiol 55(1-4), 361-70.
Rossow, K.D. (1998) Porcine reproductive and respiratory syndrome. Vet Pathol
35(1), 1-20.
Terpstra, C., Wensvoort, G. and Pol, J.M. (1991) Experimental reproduction of
porcine epidemic abortion and respiratory syndrome (mystery swine disease)
by infection with Lelystad virus: Koch's postulates fulfilled. Vet Q 13(3), 131-6.
Van Gorp, H., Van Breedam, W., Delputte, P.L. and Nauwynck, H.J. (2008)
Sialoadhesin and CD163 join forces during entry of the porcine reproductive
and respiratory syndrome virus. J Gen Virol 89(Pt 12), 2943-53.
Vincent, A.L., Thacker, B.J., Halbur, P.G., Rothschild, M.F. and Thacker, E.L. (2006)
An investigation of susceptibility to porcine reproductive and respiratory
syndrome virus between two genetically diverse commercial lines of pigs. J
Anim Sci 84(1), 49-57.

48
Wensvoort, G., Terpstra, C., Pol, J.M., ter Laak, E.A., Bloemraad, M., de Kluyver,
E.P., Kragten, C., van Buiten, L., den Besten, A., Wagenaar, F. and et al.
(1991) Mystery swine disease in The Netherlands: the isolation of Lelystad
virus. Vet Q 13(3), 121-30.
Wissink, E.H., Kroese, M.V., van Wijk, H.A., Rijsewijk, F.A., Meulenberg, J.J. and
Rottier, P.J. (2005) Envelope protein requirements for the assembly of
infectious virions of porcine reproductive and respiratory syndrome virus. J
Virol 79(19), 12495-506.

